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Abstract 
We report a case of persistent intertrigo in an 
adult, eventually diagnosed as cutaneous 
Langerhans cell histiocytosis (LCH). It is known 
that LCH has a predilection for intertriginous areas, 
however purely cutaneous disease as in our case, is 
uncommon and usually other systems are affected. 
Following the report, literature of similar cases is 
reviewed to determine possible outcomes and to 
decide on the best possible treatment options. 
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Case report 
A 29-year old obese Maltese man was 
referred to the Dermatology Department in March 
2012, with a one month history of worsening 
burning sensation in both axillae and groins, not 
responding to topical antifungal creams. A similar 
episode had apparently occurred a few months 
earlier and settled after application of a topical 
steroid/antifungal cream. He had a history of 
schizoaffective disorder and was on fluphenazine 
25mg depot injection every 5 weeks but had no 
previous history of skin or other medical problems. 
No positive symptoms were elicited on systemic 
enquiry. 
On examination there were striking, 
symmetrical, well-circumscribed, non-scaly 
erythemato-violaceous areas of induration in both 
axillae extending towards the proximal medial 
aspect of the arms (fig 1a).  The affected areas were 
warm to touch and slightly tender. There were 
similar changes beneath the abdominal apron and 
in the groins extending towards the anterolateral 
thighs (fig 1b), and over the lateral right foot and 
ankle (fig 1c). There was no palpable 
lymphadenopathy, no hepatosplenomegaly and no 
visible abnormality in the scalp, external ears, 
mouth and nails. 
An incisional biopsy from the right axilla was 
taken at presentation and empirical treatment with 
clarithromycin for 2 weeks for possible cellulitis 
was prescribed, with only minimal reduction in 
erythema at review 3 weeks later. Histology showed 
papillary dermal and deep dermal perivascular 
clusters and sheets of large ovoid cells with 
abundant pale cytoplasm and irregular, grooved 
reniform nuclei. These cells were accompanied by a 
variably dense inflammatory infiltrate composed of 
lymphocytes, eosinophils, and occasional plasma 
cells. Immunohistochemistry showed diffuse 
expression of S100 and CD1a by the large ovoid 
cells (fig 2). These features were consistent with 
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Langerhans cell histiocytosis (LCH). 
Figure 1: Indurated warm erythemato-violaceous 
plaques of LCH affecting the a) left axilla, b) right 
groin and thigh, and c) right ankle and foot 
During follow up, topical hydrocortisone 
butyrate cream twice daily gave some symptomatic 
relief. However the skin lesions persisted. Another 
infiltrated area was noticed on the right temple in 
May 2014, and this was also confirmed to be LCH 
on biopsy.  General physical examination never 
showed any other abnormalities. Routine blood 
tests showed a mildly elevated erythrocyte 
sedimentation rate ranging between 33 and 19 
mm/hr (normal <15mm/hr), raised blood glucose, 
slightly deranged liver function tests, and combined 
hyperlipidaemia. Abdominal ultrasound showed a 
fatty liver and left renal pelviureteric dilatation 
with a small stone. 
Figure 2: Histology of a biopsy taken from the right 
axilla A) H&E showing clusters and sheets of large 
ovoid cells with abundant pale cytoplasm and 
irregular, grooved reniform nuclei. B) CD1a and 
C)S100 protein positivity on Immunohistochemistry
The patient was referred to a haematologist 
for further investigation of the LCH and to a 
diabetologist for better glycaemic and lipaemic 
control.  
Hormone profile showed an elevated 
prolactin level attributable to fluphenazine. 
Complete blood count (CBC), serum protein 
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normal throughout.  Skeletal survey, computerized 
tomography scans of brain, thorax, abdomen and 
pelvis, and magnetic resonance imaging of the 
pituitary, failed to detect any other foci of LCH 
other than in the skin. 
In view of previous reports of cutaneous 
LCH responding to phototherapy, the patient was 
started on twice weekly narrow band ultraviolet B 
treatment (NB-UVB-TL01) in June 2014. Over the 
first 9 months of treatment, the lesions of LCH 
softened and faded slightly. However, no further 
improvement was observed by March 2015. The 
patient was subsequently offered psoralen 
combined with ultraviolet -A treatment (PUVA), but 
refused further treatment except topical 
hydrocortisone butyrate. He remains well apart 
from his persistent skin lesions and is being 
followed up regularly by dermatologists and a 
haematologists.  
PET scan performed in June 2015, 
confirmed disease was still limited to the affected 
areas of skin. 
Discussion 
Intertrigo is a dermatosis involving the skin 
folds. Epithelial loss caused by friction of moist 
apposing skin is the commonest cause of intertrigo. 
Secondary growth of opportunistic organisms such 
as yeasts, bacteria, and dermatophytes at such sites, 
account for most other causes. Seborrhoeic 
dermatitis, contact dermatitis, atopic dermatitis and 
psoriasis are also fairly common causes.1 This case 
adds LCH as another cause to be considered in 
cases of refractory intertrigo.  
LCH is an enigmatic condition characterized 
by tissue invasion and damage by Langerhans cells 
(LHs). These cells are large, with abundant pale 
cytoplasm and a reniform nucleus. They 
immunohistochemically stain for langerin (CD207), 
CD1a and S100, and ultrastructurally contain 
Birbeck granules. The aetiology is unclear. Debate 
whether LCH is a neoplastic process, an immune 
disorder or a genetic condition is ongoing.  
Recent literature favours the theory that LCH 
is a neoplasm with monoclonal proliferation of 
bone-marrow-derived monocytes exhibiting CD1a+ 
and langerin on immunohistochemistry (langerin 
denoting the presence of Birbeck granules where 
electron microscopy is not available). This 
particular pattern of immunohistochemistry staining 
correlates with consistent X chromosomal 
mutations on human androgen receptor genes 
(HUMARA) of lesional LC.2-4  Further support that 
LCH is a neoplastic condition is the presence of 
BRAF V600E mutations in 57% of subjects with 
LCH.4 The detection of chromosomal fragility on 
chromosomes 1, 4, 6, 7, 9, 16, 17 and 22 together 
with telomere shortening in lesional Langerhans 
cells further supports a neoplastic origin.6 
A reactive immune process is suggested by 
the presence of multiple inflammatory markers such 
as TNF- and others in lesional tissue in response 
to an unidentified stimulus.7 However, LCs remain 
immature both morphologically and functionally, 
with non-dendritic roundish cells which fail to 
stimulate an effective T-cell immune response. 
Such LCs express CD83 and CD40 which denote 
immaturity.  Cytokines enhancing maturation such 
as TNF- and IL-1, and others preventing 
maturation like TGF1 and IL-10 are detected but 
lesions tend to contain immature LCs.6-8 These cells 
can be transformed to functional maturity by the 
addition of CD40+ ligand but their morphology is 
not altered.7  
Some evidence advocating that LCH is a 
genetic condition is obtained from studies that 
demonstrated an 86% concordance in monozygotic 
twins with LCH and that LCH occurs more often in 
families where there is one affected member.9 
However it is not clear which mechanisms are 
involved.  
Chu postulates the involvement of D-
retrovirus in the pathogenesis.10 Again no definite 
proof is currently available.3 
Adult LCH is uncommon with an estimated 
yearly incidence of 1-2 per million.11 It usually, but 
not exclusively affects Caucasians, is commonest 
between 30-50 years of age, and becomes rarer with 
advancing age.12 LCH can affect one or more organ 
systems and in any combination.  The nomenclature 
of specific LCH syndromes such as Letterer-Siwe 
disease, eosinophilic granuloma, and Hand-
Schuller-Christian disease has been abandoned 
because of inconsistency of the clinical pictures. 
Instead LCH is classified by the Histiocyte Society 
into three categories according to the organ systems 
affected: (i) single system disease, (ii) multisystem 
disease, and (iii) multisystem disease with organ 
failure.10 
The clinical course of LCH is unpredictable. 
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Barres et al. suggested that BRAF-V600e mutations 
in bone marrow dendritic cells favour high risk for 
multisystem disease with organ failure, whereas if 
the mutation occurs only in lesional dendritic cells 
this would represent the low risk type of LCH.13 
Unfortunately, BRAF-V600e mutations are only 
detected in about half of the cases of LCH. Single 
system disease may remain confined to the 
respective system (low risk) or may progress to 
involve other organs (multisystem disease). 
Multisystem disease, with liver, spleen, bone 
marrow, lung and skeletal involvement, is 
considered as high risk with increased mortality.14 
In our patient, to date no extension to other organ 
systems has been noted. He is thus considered as a 
case of purely cutaneous LCH and classified as low 
risk for developing multisystem disease with organ 
failure.  
Cutaneous lesions of LCH occur in at least 
50% of adult cases of LCH and are usually 
associated with multisystem disease involving bone, 
lungs, pituitary gland and reticuloendothelial 
system. Purely cutaneous LCH occurs in only 7% 
of all patients with LCH.15 This highlights the 
singularity of our case which occurred in Malta 
with a population of 440 000. 
Cutaneous LCH has a predilection for 
intertriginous and seborrhoeic areas. Multiple 
reports of LCH affecting groins, perineum, perianal 
area, genitalia, axillae, inframammary folds, scalp 
and retro auricular areas have been published.10-
11,14,16-18,20 In spite of this, there is no published 
literature to explore why LCH preferentially affects 
such sites. We postulate that these sites may 
harbour low- grade non-specific inflammation, 
either due to friction of opposing skin surfaces or 
superficial infection which could induce the release 
of chemoattractants to LCs. 
Cutaneous manifestations of LCH are diverse 
and often pose diagnostic difficulty during physical 
examination. The commonest types of lesions 
include yellow-brown scaly patches, papules and 
nodules with or without exudate. Rarer 
manifestations of cutaneous LCH include lesions 
clinically similar to pyoderma gangrenosum, 
bruising, amoebiasis, eruptive xanthomata, prurigo 
nodularis, arthropod bites, vesicles, pustules, cherry 
spots, plane warts, Darrier’s disease, and pyogenic 
granuloma. Nail involvement with paronychia, nail 
grooving and onycholysis are also 
documented.1,14,16 Our patient had uniform, mildly 
infiltrated red-violaceous plaques without petechiae, 
scaling or ulceration in the intertriginous areas, 
scalp and ankle. Although these sites are commonly 
involved in LCH, this type of lesion appears rarely, 
if ever documented.  
The possibility that single system LCH may 
progress to multisystem disease always needs to be 
considered. Diabetes insipidus due to pituitary 
invasion by LCH is one of the best-known 
complications.17 Haematological malignancies such 
as chronic myelomonocytic leukaemia, acute 
lymphatic leukaemia and lymphomas are also 
possible complications.18  
In our case, the condition so far appears to be 
progressing only as cutaneous LCH with new 
lesions on the right ankle and right temple 
developing over a period of two years. No other 
abnormality attributable to LCH or haematological 
malignancy has been found in other systems despite 
thorough investigation.  
In our patient, NB-UVB had a noticeable but 
short-lived effect, thus further therapeutic 
modalities were considered to try to halt the 
condition. Such modalities would include PUVA, 
local radiotherapy, imiquimod, systemic 
isotretinoin, low dose methotrexate, cyclosporine, 
topical nitrogen mustard, thalidomide and 
intralesional interferon- or interferon-18-23,27 This 
order of single-agent treatment offers successive 
options of treatment with the intention of limiting 
adverse effects. However, the efficacy of individual 
treatments was inconsistent with several reports of 
treatment failure and relapse.27 Our patient refused 
PUVA and other treatments, despite his concern 
about the cosmetic appearance of the lesion on the 
scalp. 
For resistant cases of LCH or multisystem 
disease affecting vital organs, chemotherapy 
regimens are often used. These include 
combinations of chlorodeoxyadenosine, vincristine, 
vinblastine, cytarabine, 6-mercaptopurine, 
cyclophosphamide, etoposide and systemic 
steroids.18,20,25- 27
Our patient needs lifelong follow-up in order 
to monitor any extension of his condition, relapses 
and any other arising complications. 
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